Gonal-f® + Long GnRH agonist + GnRH antagonist
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome
Trial Timeline
Dec 31, 2015 → Jun 28, 2017
NCT ID
NCT02607293About Gonal-f® + Long GnRH agonist + GnRH antagonist
Gonal-f® + Long GnRH agonist + GnRH antagonist is a pre-clinical stage product being developed by Merck for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02607293. Target conditions include Polycystic Ovary Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02607293 | Pre-clinical | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome